The metabolic syndrome in HIV.

Abstract

The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.

• Authors: Signe W Worm, Jens D Lundgren
• Journal: Best practice & research. Clinical endocrinology & metabolism (Best Pract Res Clin Endocrinol Metab) Vol. 25 Issue 3 Pg. 479-86 (Jun 2011) ISSN: 1878-1594 [Electronic] Netherlands
• PMID: 21663841 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Anti-HIV Agents

Topics

• Anti-HIV Agents (adverse effects, therapeutic use)
• Cardiovascular Diseases (epidemiology)
• Female
• HIV (pathogenicity)
• HIV Infections (drug therapy, physiopathology)
• Humans
• Incidence
• Male
• Metabolic Syndrome (diagnosis, epidemiology, etiology)
• Prevalence
• Risk Factors
• Sex Factors